Phil Newman is the Editor-in-Chief at Longevity.Technology and has been involved in the longevity industry since 2018. He has a background in sales and marketing, having built his career working in early-stage startup businesses. Newman’s entry into the longevity industry was sparked by his reading about Juvenescence and their $50 million funding in 2018. He then delved deeper into the field, studying the work of scientists and clinicians, and decided to invest his own money into the industry. He launched Longevity.Technology in September 2019, employing journalists and establishing offices to cover the longevity space. Newman has been actively involved in promoting the industry and its advancements, including through his talks and presentations on longevity biotechnology investing